- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01160770
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome (LGS)
February 22, 2018 updated by: Lundbeck LLC
The objective of this study is to evaluate the long-term safety and effectiveness of open-label clobazam in the treatment of drop seizures in subjects with LGS.
Study Overview
Detailed Description
This multi-center, open-label study is designed to evaluate the long-term safety and effectiveness of clobazam as adjunctive therapy in subjects with LGS.
Subjects enrolled in Lundbeck LLC (formerly Ovation Pharmaceuticals, Inc.) sponsored studies 13108A/OV1002/NCT00162981 and 13110A/OV1012/NCT00518713 who either completed the study or who prematurely discontinued were offered the opportunity to rollover into this open-label study.
Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours.
After 48 hours, investigators will be able to increase, decrease or maintain the subject's dose, up to a maximum target daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
During the treatment period, seizures will be recorded during the week preceding each study visit or 30 days immediately following each study visit (dependent on Amendment approval).
The subject or subject's caregiver will record daily counts of seizures, including drop seizures in the subject's seizure diary.
Study Type
Interventional
Enrollment (Actual)
267
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 months to 58 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject or subject's legally authorized representative (LAR) must sign and date the institutional review board (IRB)/independent ethics committee (IEC) approved Informed Consent Form/Health Insurance Portability and Accountability Act (HIPAA) Authorization (if required) prior to study participation.
- Previous participation in Lundbeck-sponsored LGS study.
- Subject must weigh ≥12.5 kilograms.
- Male or female subjects must have been between 2 and 60 years of age at the time of the enrollment in the Phase 3 double-blind study (13110A/OV1012/NCT00518713) or between 2 and 30 years of age at the time of the enrollment in the Phase 2 double-blind study (13108A/OV1002/NCT00162981) study.
If female:
- Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study.
- Subject is not breastfeeding.
- Subjects of childbearing potential must have a negative serum pregnancy test at Study Day 1.
- In the investigator's opinion, parent or caregiver must be able to keep an accurate seizure diary.
Exclusion Criteria:
- Greater than 14 days have elapsed since the subject received his/her last dose of study medication in the previous Lundbeck-sponsored LGS study.
- Subject had a serious or severe adverse event in the previous Lundbeck-sponsored LGS study that in the opinion of the investigator was probably or definitely related to clobazam use and precludes safe use of clobazam.
- Subject has had an anoxic episode requiring resuscitation within 6 months of study entry.
- Subject has a history of an allergic reaction or significant sensitivity to benzodiazepines or to any of the other ingredients in clobazam tablets.
- Subject is taking more than 3 concurrent anti-epileptic drugs (AEDs). NOTE: Vagal Nerve Stimulator (VNS) or ketogenic diet is allowed and will not be counted in the three allowed AEDs.
- Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for idiopathic nephrotic syndrome or asthma.
- If the subject is taking felbamate, has been taking it for less than 1 year prior to study entry or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events.
- Subject has experienced an idiosyncratic reaction to an AED, e.g., carbamazepine with resulting aplastic anemia or agranulocytosis, topiramate with resulting metabolic acidosis, felbamate with resulting aplastic anemia or hepatic failure, or lamotrigine with resulting skin irritation and/or rash.
- Subject has shown any clinically significant history of hyper-sensitivity to central nervous system (CNS) active medications leading to neurobehavioral aberrations (e.g., increased biting, scratching, kicking, or hitting).
- Subject has taken or used any investigational drug or device in the 30 days prior to screening, with the exception of clobazam in a Lundbeck-sponsored study.
- Subject has a clinically significant unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, or pulmonary disease or ongoing malignancy.
- Subject has a diagnosis of sleep apnea.
- Subject has a compromised respiratory function or severe respiratory insufficiency.
- Subject has a history of severe muscle weakness, including myasthenia gravis.
- Subject has a clinically significant abnormal laboratory value or electrocardiogram (ECG) abnormality.
- Subject has progressive lesion confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- Subject has a history of drug or alcohol abuse.
- Subject has a history of poor compliance on past antiepileptic therapy.
- Subject has inadequate supervision by parent or guardian.
- For any reason, the subject is considered by the investigator to be an unsuitable candidate for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clobazam
|
Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit.
Bottles may be dispensed between visits if necessary.
Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours.
After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment
Time Frame: Baseline to month 36
|
Number of drop seizures was obtained from seizure diaries
|
Baseline to month 36
|
Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the Last 30-day Assessment
Time Frame: Baseline to month 36
|
Number of drop seizures was obtained from seizure diaries
|
Baseline to month 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Patients Considered Treatment Responders Defined as Those With a ≥25%, ≥50%, ≥75%, 100% Reduction in Drop Seizures Based on the 7-day Assessment
Time Frame: Baseline to month 36
|
Number of drop seizures obtained from seizure diaries
|
Baseline to month 36
|
Percent of Patients Considered Treatment Responders Defined as Those With a ≥25%, ≥50%, ≥75%, 100% Reduction in Drop Seizures Based on the Last 30-day Assessment
Time Frame: Baseline to month 36
|
Number of drop seizures obtained from seizure diaries
|
Baseline to month 36
|
Investigator Global Evaluations of the Patient's Overall Change in Symptoms
Time Frame: Baseline to month 36
|
The physician was asked to rate the patient's overall change in symptoms since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
|
Baseline to month 36
|
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms
Time Frame: Baseline to month 36
|
The parent/caregiver was asked to rate the patient's overall change in symptoms since the beginning of clobazam treatment by checking "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse".
|
Baseline to month 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ng YT, Conry J, Paolicchi J, Kernitsky L, Mitchell W, Drummond R, Isojarvi J, Lee D, Owen R; OV-1004 study investigators. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav. 2012 Dec;25(4):687-94. doi: 10.1016/j.yebeh.2012.09.039. Epub 2012 Nov 7.
- Gidal BE, Wechsler RT, Sankar R, Montouris GD, White HS, Cloyd JC, Kane MC, Peng G, Tworek DM, Shen V, Isojarvi J. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology. 2016 Oct 25;87(17):1806-1812. doi: 10.1212/WNL.0000000000003253. Epub 2016 Sep 28.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
June 18, 2010
First Submitted That Met QC Criteria
July 9, 2010
First Posted (Estimate)
July 12, 2010
Study Record Updates
Last Update Posted (Actual)
March 21, 2018
Last Update Submitted That Met QC Criteria
February 22, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epileptic Syndromes
- Disease
- Genetic Diseases, Inborn
- Epilepsy
- Syndrome
- Lennox Gastaut Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- GABA Agents
- Anticonvulsants
- GABA-A Receptor Agonists
- GABA Agonists
- Clobazam
Other Study ID Numbers
- 13109A
- OV1004 (Other Identifier: Lundbeck LLC ((Formerly Lundbeck Inc. and before that Ovation Pharmaceuticals (OV)))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lennox-Gastaut Syndrome
-
Eisai Inc.TerminatedLennox-Gastaut Syndrome (LGS)Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
-
TakedaRecruitingLennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
-
TakedaCompletedLennox Gastaut Syndrome (LGS)United States, China, Canada, France, Hungary, Australia, Poland, Spain, Japan, Belgium, Greece, Serbia, Germany, Italy, Latvia, Netherlands, Russian Federation, Ukraine
-
University College, LondonKing's College London; King's College Hospital NHS Trust; University of Oxford; Great Ormond Street Hospital for Children NHS Foundation TrustRecruitingEpilepsy | Lennox-Gastaut Syndrome, IntractableUnited Kingdom
-
TakedaRecruitingDravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)Spain
-
NeuroPaceNational Institute of Neurological Disorders and Stroke (NINDS); University...RecruitingEpilepsy | Seizures | Lennox Gastaut Syndrome | Lennox-Gastaut Syndrome, Intractable | Seizures, GeneralizedUnited States
-
TakedaActive, not recruitingEpilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
-
GlaxoSmithKlineBausch Health Americas, Inc.Terminated
-
EpygenixNot yet recruiting
-
Eisai LimitedCompletedLennox-Gastaut SyndromeJapan
Clinical Trials on Clobazam
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States, Belarus, India, Australia, Lithuania
-
Lundbeck LLCCompletedEpilepsy | Epilepsy, Generalized | SeizuresUnited States
-
Boston Children's HospitalLundbeck LLCCompletedElectrical Status Epilepticus in SleepUnited States
-
University Hospital Inselspital, BerneCompleted
-
St. Joseph's Hospital and Medical Center, PhoenixH. Lundbeck A/SUnknownRefractory EpilepsyUnited States
-
University Hospital, GenevaCompleted
-
Lars Kristian MunckPierre and Marie Curie UniversityCompletedBile Acid Malabsorption | Chronic DiarrheaDenmark
-
Instituto de Investigação em ImunologiaButantan InstituteUnknownCancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.Brazil
-
Pavel KleinH. Lundbeck A/SUnknown
-
Hugo W. Moser Research Institute at Kennedy Krieger...Completed